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Cross talk between EBV and telomerase: the role of
TERT and NOTCH2 in the switch of latent/lytic cycle
of the virus
S Giunco1, A Celeghin1, K Gianesin1, R Dolcetti2, S Indraccolo3 and A De Rossi*,1,3
Epstein–Barr virus (EBV)-associated malignancies, as well as lymphoblastoid cell lines (LCLs), obtained in vitro by EBV infection
of B cells, express latent viral proteins and maintain their ability to grow indefinitely through inappropriate activation of telomere-
specific reverse transcriptase (TERT), the catalytic component of telomerase. Our previous studies demonstrated that high levels
of TERT expression in LCLs prevent the activation of EBV lytic cycle, which is instead triggered by TERT silencing. As lytic
infection promotes the death of EBV-positive tumor cells, understanding the mechanism(s) by which TERT affects the latent/lytic
status of EBV may be important for setting new therapeutic strategies. BATF, a transcription factor activated by NOTCH2, the major
NOTCH family member in B cells, negatively affects the expression of BZLF1, the master regulator of viral lytic cycle. We therefore
analyzed the interplay between TERT, NOTCH and BATF in LCLs and found that high levels of endogenous TERT are associated
with high NOTCH2 and BATF expression levels. In addition, ectopic expression of TERT in LCLs with low levels of endogenous
telomerase was associated with upregulation of NOTCH2 and BATF at both mRNA and protein levels. By contrast, infection of
LCLs with retroviral vectors expressing functional NOTCH2 did not alter TERT transcript levels. Luciferase reporter assays,
demonstrated that TERT significantly activated NOTCH2 promoter in a dose-dependent manner. We also found that NF-κB pathway
is involved in TERT-induced NOTCH2 activation. Lastly, pharmacologic inhibition of NOTCH signaling triggers the EBV lytic cycle,
leading to the death of EBV-infected cells. Overall, these results indicate that TERT contributes to preserve EBV latency in B cells
mainly through the NOTCH2/BAFT pathway, and suggest that NOTCH2 inhibition may represent an appealing therapeutic strategy
against EBV-associated malignancies.
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Epstein–Barr virus (EBV), a human herpesvirus with potent
B-cell transforming activity in vitro, is linked to a number of
B-cell malignancies in vivo.1 EBV infection transforms human
primary resting B lymphocytes into actively proliferating cells
that may generate immortalized lymphoblastoid cell lines
(LCLs). LCLs are an in vitro model of EBV-driven B-cell
malignancies, such as post-transplant lymphoproliferative
disorders and non-Hodgkin lymphomas. EBV-associated
B-cell malignancies and LCLs express latent viral proteins
and maintain their ability to grow indefinitely through inap-
propriate activation of telomerase.2–4
Telomerase is a ribonucleoprotein complex containing an
internal RNA template and a catalytic protein with telomere-
specific reverse transcriptase activity (TERT) that maintains
telomeres at the ends of eukaryotic chromosomes, thus
preventing cell senescence and apoptosis.5,6 Recent studies
have suggested that, besides maintenance of telomere
length, TERT is involved in several other cell functions.7,8
Our previous studies have demonstrated that TERT
expression has an important role in preventing the EBV lytic
cycle in LCLs, thereby favoring the induction andmaintenance
of EBV latency in primary B lymphocytes, a prerequisite for
EBV-driven transformation. Indeed, high levels of endogenous
TERT or ectopic TERT expression in telomerase-negative
EBV-infected cells prevent viral lytic cycle induction. By
contrast, TERT silencing by specific siRNA or short-hairpin
(sh) RNA induces the expression of BZLF1, EBVearly antigen
diffuse (EA-D) and glycoprotein 350 (gp350) EBV lytic proteins
and triggers a complete lytic replication of the virus. This
occurs in both EBV-immortalized LCL and fully transformed
EBV-positive Burkitt lymphoma (BL) cell lines, thus supporting
the concept that TERT is a critical regulator of the balance
between EBV latency and lytic replication in B cells.3,9–10 The
fine mechanisms by which TERT level modulates the
expression of EBV lytic proteins are still unclear. According
to our previous findings, activation of the EBV lytic cycle
triggered by TERT inhibition may depend on modulation of
BATF, a negative regulator of BZLF1, the main inducer of the
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viral lytic cycle.9 BATF is a transcription factor mainly
expressed in hematopoietic tissues and in B cells infected with
EBV.11–13 Interestingly, BATF is a target gene of NOTCH
signaling in B cells.13 The NOTCH gene family encodes
transmembrane receptors that modulate differentiation, pro-
liferation and apoptotic programs in response to extracellular
stimuli.14–17 NOTCH signaling is activated by the interaction of
the extracellular domain of NOTCH with one of its ligands,
belonging to the delta-like and jagged families. This interaction
induces a conformational change in NOTCH, resulting in two
proteolytic cleavages mediated by ADAM protease and
gamma-secretase, and cytoplasmic release of the NOTCH
intracellular domain (NOTCH-ICD), allowing its translocation
to the nucleus, where it participates in transcriptional regula-
tion of target genes.18
In particular, NOTCH2 has an important role in the
development of marginal zone B cells,19 and NOTCH2 gene
mutations or overexpression can be detected in B-cell
malignancies.20–30 These observations, together with the
demonstration that NOTCH2 can induce the expression of
BATF,13 prompted us to examine the possible involvement of
NOTCH2 in the mechanisms underlying the regulation of EBV
latent/lytic status affected by TERT in LCLs. As viral lytic
replication is associated with the death of infected cells,
discovering the pathways involved in the mechanisms by
which TERT regulates the balance between EBV latency and
lytic replication may be useful in designing new strategies to
treat EBV-driven malignancies.
Results
BATF and NOTCH2 are expressed at high levels in TERT-
positive LCLs. We first examined the expression of BATF
and NOTCH2 in LCLs expressing various levels of endogen-
ous TERT. LCLs greatly differed in their timing of TERT
expression and telomerase activation; in fact, they exhibit
telomerase activity (TA) since their early culture passages
after EBV infection or else become telomerase positive
during their establishment in culture.2–4 Figures 1a and b
show seven representative LCLs with low (4134/Early, 4810/
Early and 4193) or high (4134/Late, 4810/Late, 4815 and
4141) levels of endogenous TERT and TA; LCLs with low/
undetectable TERT levels and TA had significantly lower
BATF mRNA levels (P=0.0215; Figure 1c). TERT-positive
LCLs also had more than threefold higher NOTCH2 transcript
levels than TERT-negative LCLs (P=0.0174; Figure 1d).
Western blot analysis showed higher levels of NOTCH2
protein in TERT-positive LCLs, thus supporting results of the
transcript analysis (Figure 1e). Overall, these findings
suggest a possible interplay between TERT, BATF and
NOTCH2 levels in LCL cells.
Ectopic expression of TERT is followed by increased
expression of functional NOTCH2 protein. To investigate
whether TERT could modulate NOTCH2 expression, we
examined 4134/Early cells transfected with a retroviral vector
containing TERT (4134/TERT+) or with the control vector
(4134/BABE); 4134/TERT+ cells expressing ectopic TERT
showed much higher levels of TERT transcripts than parental
or control 4134/BABE cells (Figure 2a). Increased TERT
mRNA levels were paralleled by a concomitant increase in TA
(Figure 2b). Cells expressing ectopic TERT showed
increased levels of both NOTCH2 and BATF transcripts and
relative proteins (Figures 2c and d). Interestingly, forced
TERTexpression was accompanied by a significant increase
in transcripts and protein expression of jagged 1 (JAG1), one
of the NOTCH ligands (Figures 2d and e). The expression of
NOTCH2 and JAG1 in 4134/TERT+ cells was also asso-
ciated with increased NOTCH signaling, as indicated by
upregulation of transcripts of hes family bHLH transcription
factor 1 (HES1), a canonical target gene activated by the
NOTCH pathway (Figure 2e). NOTCH signaling in our LCL
model is probably activated by interactions between cells
expressing both JAG1 and NOTCH2, which may occur in the
tight clumps typically formed in B cells after EBV
infection.31,32 Upregulation of JAG1 and HES1 expression
was also detected in cells expressing high levels of
endogenous TERT transcripts (data not shown).
NOTCH2-ICD does not induce TERT expression. To
ascertain whether NOTCH2 could also induce TERT expres-
sion, 4134/Early cells were infected with a retroviral vector
expressing the functional NOTCH2-ICD (4134/MigRI-ICN2 or
4134/MSCVpuro-ICN2) or with a control vector (4134/BABE).
NOTCH2 overexpression in infected cells was confirmed by
PCR amplification (Figure 3a) and, as expected, was followed
by increased expression of the NOTCH target gene HES1
(Figure 3b). As shown in Figure 3c, ectopic expression of
NOTCH2-ICD did not significantly modify the level of TERT
transcripts. Since NOTCH2 participates directly in transcrip-
tional regulation of nuclear genes, we performed additional
experiments to confirm that NOTCH2 did not activate TERT
expression. TERT-negative U2OS cells were co-transfected
with phTERTpromoterLuc, expressing luciferase under the
control of the TERT promoter, and a plasmid expressing
NOTCH2-ICD (pMigRI-ICN2 or pMSCVpuro-ICN2), or a
plasmid expressing v-myc avian myelocytomatosis viral
oncogene homolog (MYC; pMT2TMyc), a well-known acti-
vator of TERT promoter. Luciferase analysis showed that,
unlike MYC, NOTCH2-ICD does not activate the TERT
promoter (Figure 3d).
TERT transactivates the NOTCH2 promoter via NF-κB
signaling. The finding that TERT overexpression increased
NOTCH2 mRNA levels prompted us to ascertain whether the
NOTCH2 promoter could be activated by TERT. HCT116
cells were co-transfected with the pGL3N2PR-2327/-99
plasmid, carrying the luciferase gene under the control of
NOTCH2 promoter33 and with pEGFP–hTERT, a plasmid
encoding a enhanced green fluorescent protein (EGFP)–
TERT fusion protein, or the pEGFP-C1 vector as a control.34
Luciferase analysis disclosed that the NOTCH2 promoter
was significantly activated by ectopic TERT expression in a
dose-dependent manner (Figure 4a).
Recent studies have indicated a telomere-independent role
for TERTas a transcriptional modulator of the Wnt and NF-κB
signaling pathways.35–37 Therefore, in order to identify the
mechanism exploited by TERT to induce NOTCH2 expres-
sion, we examined the effects of Wnt and NF-κB inhibitors on
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the regulation of the NOTCH2 promoter by TERT. HCT116
cells were co-transfected with pGL3N2PR-2327/-99 and
pEGFP–hTERT or with pGL3N2PR-2327/-99 and pEGFP-
C1 as control, and cultured in serial dilutions of the NF-κB
signaling inhibitor NF-κB activation inhibitor (N-AI) or dimethyl-
sulfoxide (DMSO). Luciferase reporter assay performed 24 h
after co-transfection showed that N-AI treatment reduced
NOTCH2 promoter activation by TERT in a dose-dependent
manner compared with DMSO-treated cells (Figure 4b). To
ascertain the specificity of the N-AI effect, we performed
parallel experiments by co-transfecting HCT116 cells with
pGL3N2PR-2327/-99 and pCGN-HA-S33Y-β-catenin, a plas-
mid encoding an S33Y-mutated β-catenin protein known to
activate the NOTCH2 promoter through the Wnt pathway.33
Results showed that N-AI treatment did notmodify the ability of
S33Y-β-catenin to activate the NOTCH2 promoter compared
with DMSO-treated cells (Figure 4c). Conversely, experiments
with theWnt signaling inhibitor XAV-939 showed that XAV-939
did not counteract NOTCH2 promoter induction by TERT
compared with DMSO-treated cells (data not shown). These
data suggest that NF-κB, but not Wnt signaling, is involved in
the TERT-mediated activation of NOTCH2 expression.
To further investigate the involvement of NF-κB signaling in
the regulation of the NOTCH2 promoter by TERT, we
performed the luciferase reporter assay with a smaller NOTCH2
luciferase promoter reporter construct (pGL3N2PR-110),
covering the most proximal LEF-1/TCF-site but lacking
two putative NF-κB binding motifs.33,38 In agreement with a
previous study,33 we observed that luciferase activity was
similarly increased by co-transfection with pCGN-HA-S33Y-β-
catenin with either pGL3N2PR-2327/-99 or pGL3N2PR-110
(7.5-fold increase for pGL3N2PR-2327/-99 and 6.6-fold
increase for pGL3N2PR-110 compared with co-transfection
with the control pcDNA3 plasmid; Figure 4d). In contrast,
pEGFP–hTERT activated pGL3N2PR-110 significantly less
efficiently than pGL3N2PR-2327/-99 (Po0.001), (3.4-fold
Figure 1 High levels of TERTare associated with high levels of BATF and NOTCH2 expression in LCLs. TERT levels, telomerase activity (TA), BATF and NOTCH2 expression
in several LCLs. (a) TERT transcripts were quantified by real-time PCR. Values are means and S.D. (bar) of three replicates. (b) TA was analyzed by TRAP assay. TL, telomerase
ladder; ITAS, internal telomerase assay standard. Panels are representative of three separate analyses. (c) BATF and (d) NOTCH2 transcripts were quantified by real-time PCR.
Relative units were calculated according to 2−ΔCt formula, with HPRT1 as housekeeping gene. Values are means and S.D. (bar) of three replicates. (e) Expression of NOTCH2
and housekeeping α-tubulin proteins was assessed by western blot. Panels are representative of three separate analyses. Presence (+) or absence (− ) of TA in cell cultures is
reported below
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increase for pGL3N2PR-110 and 6.8-fold increase for
pGL3N2PR-2327/-99 compared with co-transfection with the
control pEGFP-C1 plasmid; Figure 4d). Taken together, these
results demonstrate that TERT activates the NOTCH2
promoter and that this effect is mostly mediated by the
NF-κB signaling pathway.
Inhibition of NOTCH signaling triggers EBV lytic cycle.
We have previously demonstrated that, in the LCL system,
the viral latent membrane protein 1 (LMP1) activates TERTat
transcriptional level,39 whereas TERT silencing triggers the
viral lytic cycle.9 This effect is associated with downregulation
of BATF, a transcription factor able to modulate BZLF1
expression. According to these previous findings, we
hypothesized that TERT can affect EBV latent/lytic status
by modulating NOTCH2 expression which, in turn, may
influence BATF expression;13 thus, inhibition of NOTCH2
signaling was predicted to induce activation of the EBV lytic
cycle. To test this hypothesis, we treated 4134/TERT+ with
gamma-secretase inhibitors (GSIs), including compound E
(CompE) and dibenzazepine (DBZ). GSIs are compounds
that block the final cleavage of the precursor form of NOTCH,
thus preventing generation of ICD and inhibiting NOTCH
signaling. GSIs treatment of 4134/TERT+ cells reduced both
Figure 2 Ectopic expression of TERT induces expression of functional NOTCH2 protein. 4134/Early cells were infected with retroviral vector expressing TERT (4134/TERT+)
or with control empty vector (4134/BABE). (a) TERT transcripts were quantified by real-time PCR. Values are means and S.D. (bar) of three replicates. (b) Telomerase activity was
tested by TRAP assay. TL, telomerase ladder; ITAS, internal telomerase assay standard. Panel is representative of three separate analyses. (c) NOTCH2 and BATF transcripts
were quantified by real-time PCR. Values are the means and S.D. (bar) of three replicates. (d) Expression of NOTCH2, BATF, JAG1 and housekeeping α-tubulin proteins was
assessed by western blot. Panels are representative of three separate analyses. (e) JAG1 and HES1 transcripts were quantified by real-time PCR. Values are means and S.D.
(bar) of three replicates. *Po0.05
TERT and NOTCH2 in the EBV latent/lytic status
S Giunco et al
4
Cell Death and Disease
the canonical NOTCH target gene, HES1 and BATF expression
in a time- and dose-dependent manner (Figures 5a and b).
Western blot analysis confirmed that the cleavage of
NOTCH2 was inhibited by treatment with GSIs (Figure 5c).
Inhibition of NOTCH signaling at 5 days also resulted
in the expression of lytic viral BZLF1 and E-AD genes
(Figures 5c and d). GSI treatment consistently resulted in a
remarkable increase in the number of positive cells expressing
late viral lytic gp350 (fromo1% in control cell cultures to ~35%
in cell cultures treated with 5μM CompE or 0.5 μM DBZ;
Figure 5e). B95.8 cells were employed as positive control
for EBV lytic protein expression (Supplementary Figure 1).
The complete induction of the viral lytic cycle was confirmed
by the release of EBV virions, as shown by increased EBV
DNA levels in DNase-treated culture supernatants (Figure 5f)
after 5 days of GSI treatment compared with supernatant
from untreated control cells.
As the EBV lytic cycle promotes the death of infected cells,
we studied the possible pro-apoptotic effect of GSI treatment
on EBV-infected cells. Treatment of 4134/TERT+ cells for
5 days with 5 μM of CompE or 0.5 μM of DBZ induced an
increase in the number of apoptotic cells (by 430%)
compared with DMSO-treated cells (Figure 6a). The number
of cells undergoing apoptosis after GSI treatment was
Figure 3 NOTCH2 does not induce TERTexpression. 4134/Early cells were infected with retroviral vectors expressing NOTCH2-ICD (4134/MigRI-ICN2 or 4134/MSCVpuro-
ICN2) or with control vector (4134/BABE), and analyzed at indicated hours (h) post infection for NOTCH2, HES1 and TERT. (a) NOTCH2 (upper panel) and housekeeping
GAPDH (lower panel) mRNAwere analyzed by RT-PCR. Panels are representative of three separate analyses. (b) HES1 transcripts were quantified by real-time PCR. Values are
means and S.D. (bar) of three replicates. (c) TERT transcripts were analyzed by real-time PCR. Values are means and S.D. (bar) of three replicates. (d) U2OS cells were co-
transfected with a plasmid expressing luciferase under the control of the TERT promoter (phTERTpromoterLuc) and with vectors expressing MYC (pMT2TMyc) or NOTCH2-ICD
(pMigRI-ICN2 or pMSCVpuro-ICN2) or with control vector (pMT2T). A plasmid expressing bacterial β-Gal gene (pCMV-βGal) was employed as an internal control for transfection
efficiency. Luciferase assay was performed 72 h post transfection. Values are means and S.D. (bar) of three separate experiments
TERT and NOTCH2 in the EBV latent/lytic status
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consistent with the percentage of cells positive for late lytic
gp350 viral protein. In agreement with published data,40 in
EBV-negative BL41 cells, treatment with GSIs (5 μM of
CompE or 0.5 μM of DBZ), only slighty increased the
percentage of apoptotic cells (Supplementary Figure 2). In
EBV- and TERT-negative U2OS cells, treatment with 10 μM of
CompE or with 1 μMof DBZ did not alter cell viability compared
with untreated control cells (data not shown). Furthermore, in
view of the emerging interest in approaches combining lytic
cycle inducers with antiviral drugs to treat EBV-driven tumors,
we studied the apoptotic effect of combined treatment with GSI
and ganciclovir (GCV), an antiviral pro-drug that is activated by
viral lytic protein kinase.41–43 As shown in Figure 6a, the
combined treatment of 4134/TERT+ cells with GSI and GCV
Figure 4 Transcriptional activation of NOTCH2 promoter by TERT. (a) HCT116 cells were co-transfected with a plasmid expressing luciferase under control of NOTCH2
promoter (pGL3N2PR-2327/99) and with 1 or 2 μg of plasmid expressing TERT (pEGFP–hTERT) or control vector (pEGFP-C1). (b) HCT116 cells were co-transfected with
NOTCH2 reporter plasmid pGL3N2PR-2327/99 and with pEGFP–hTERT or control pEGFP-C1. Three hours before co-transfection cells were treated with indicated
concentrations of N-AI or with DMSO as control. (c) HCT116 cells were co-transfected with NOTCH2 reporter plasmid pGL3N2PR-2327/99 and with a plasmid encoding an S33Y-
mutated β-catenin protein (pCGN-HA-S33Y-βcatenin) or a control plasmid (pcDNA3). Three hours before co-transfection cells were treated with indicated concentrations of N-AI
or with DMSO as control. (d) HCT116 cells were co-transfected with vectors allowing the expression of S33Y-β-catenin (pCGN-HA-S33Y-βcatenin) or TERT (pEGFP–hTERT) or
with control vectors (pcDNA3 and pEGFP-C1) and with a plasmid expressing luciferase under control of larger NOTCH2 promoter (pGL3N2PR-2327/99) or smaller NOTCH2
promoter (pGL3N2PR-110). A plasmid expressing bacterial β-Gal (pCMV-βGal) gene was also co-transfected in each experiment as internal control for transfection efficiency.
Luciferase assay was performed 24 h post transfection. Values are means and S.D. (bar) of four separate experiments. NS, not significant; *Po0.05
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further increased the rates of apoptotic cells compared with
cells treated with GSI alone (Figure 6a). However, treatment
with GCV alone did not affect cell viability. The increased rate
of apoptotic cells in cultures treated with a combination of GCV
and GSI compared with GSI treatment alone suggests that in
some GSI-treated cells the EBV lytic reactivation is abortive,
but sufficient to produce the early lytic EBV protein kinase able
to activate the pro-drug GCV.44 Lastly, activation of the EBV
lytic cycle after GSI treatment was also observed in EBV-
positive cells of BL cell line BL41/B95.8 (data not shown). As
observed in 4134/TERT+, also in BL41/B95.8 cells GSI
treatment induced a pro-apoptotic effect enhanced by
combined treatment, GSI with GCV (Figure 6b), indicating
that this is a general phenomenon for EBV-carrying B
lymphocytes.
Discussion
Despite their pathogenic importance, the mechanisms under-
lying EBV reactivation in vivo are poorly understood. Available
data obtained from in vitromodels indicate that EBV lytic cycle
can be elicited by treatment of latently infected cells with a
Figure 5 Inhibition of NOTCH signaling induces EBV lytic cycle. 4134/TERT+ cells were treated for 3 and 5 days with indicated concentrations of GSIs (CompE or DBZ) or
DMSO as control. HES1 (a) and BATF (b) transcripts were quantified by real-time PCR. Values are the means and S.D. (bar) of three replicates. (c) Expression of lytic EA-D viral
protein, cellular NOTCH2 and housekeeping α-tubulin was assessed by western blot after 5 days of GSIs treatment. Panels are representative of three separate experiments.
(d) BZLF1 (upper panels) and housekeeping GAPDH (lower panels) mRNAwere analyzed by RT-PCR after 5 days of GSI treatment. Panels are representative of three separate
experiments. NT, no treated cells. (e) gp350 protein expression in 4134/TERT+ cells at 5 days of treatment with indicated concentration of GSI or with DMSO as control (20x).
Scale bar, 100 μm. The inserts were 40x magnification. (f) Real-time PCR quantification of EBV DNA in cell culture supernatants after ultracentrifugation and DNase treatment
after 5 days of GSI treatment. Values are the means and S.D. (bar) of three replicates
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variety of reagents including 12-O-tetradecanoyl-phorbol-
1-acetate, calcium ionophores, sodium butyrate, anti-
immunoglobulin antibodies and TGF-β.45− 47 The effects of
all these reagents converge on the upregulation of two
EBV immediate–early genes, BZLF1 and BRLF1,
which orchestrate the activation of viral lytic replication.48
Nevertheless, in all experimental conditions investigated so
far, only a fraction of cells treated with these reagents enter the
lytic cycle, the remainder of the population being refractory to
lytic replication.49,50 Therefore, identification of cellular factors
that regulate the balance between latency and lytic replication
of EBV is critical for better understanding of the complex
interplay between virus and infected cells.
It is well established that TERTactivation is a prerequisite for
an efficient EBV-driven B-cell immortalization.2–4 Accumulating
evidence indicates that TERT may have additional functions,
Figure 6 Effect of GSIs and GCV on cell viability. 4134/TERT+ cells (a) and BL/41B95.8 cells (b) were cultured for 5 days in presence of GSI (5 μM of CompE or 0.5 μM of
DBZ) with or without 100 μM of GCV. Cells were labeled with annexin V/PI and analyzed by flow cytometry. Panels are representative of three separate experiments. Percentages
of apoptotic cells are shown in the graphs on the bottom. Values are means and S.D. (bar) of three separate experiments
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beyond its role in preserving telomere homeostasis.7,8 Our
previous studies have demonstrated that high levels of TERT
expression in LCLs prevent the induction of the EBV lytic
cycle, which is instead triggered by TERT silencing.3,9
However, the fine mechanisms by which TERT levels affect
EBV lytic/latent status have not yet been elucidated. In the
present study, we demonstrate that high expression of TERT
in LCLs induces an increase in levels of NOTCH2 and its target
genes, including BATF, an inhibitor of the expression of
BZLF1, the main EBV lytic cycle inducer. Therefore, our
findings show that TERT contributes to preserve EBV latency
in B cells mainly through NOTCH2-dependent BATF
activation.
BATF is a member of the AP-1/ATF superfamily of basic
leucine zipper transcription factors, able to form heterodimers
with Jun proteins to bind to AP-1 consensus sites
preferentially.12 Available data indicate that BATF expression
may antagonize the B-cell growth and inhibit pro-apoptotic
gene expression in these cells.12 EBV nuclear antigen 2
(EBNA2) has been shown to induce BATF immediately after
infection of primary B cells.13 Notably, EBNA2 could be
regarded as a functional homolog of an active NOTCH
receptor, due to its ability to be tethered to promoter regions
by interaction with the DNA-binding protein RBPJ.51,52 EBNA2
and NOTCH2 appear to be partially interchangeable as
regards to their ability to activate target genes and modulate
signaling pathways in B-cell lines.51 In the absence of EBNA2,
NOTCH may transcriptionally upregulate the expression of
EBV LMP 2A, which in turn activates the NOTCH pathway in a
positive feedback loop.53,54 On these grounds, our results
indicate that, in B cells, TERT activates the NOTCH/BATF
cascade, a cellular pathway that is functionally hijacked by
EBV for critical regulation of the balance between latency and
lytic replication, and induction of immortalization.
The role of NOTCH signaling in B-cell lymphomagenesis is
not yet clear, and only limited data are available, particularly for
EBV-driven lymphomas; nevertheless, dysfunctions of this
pathway may be involved in neoplastic development.15 In
particular, deregulation of NOTCH2 signaling and consequent
CD23 upregulation have been observed in B-cell malignan-
cies, such as B-cell chronic lymphocytic leukemia.55,20–24
Overexpression of NOTCH2 has been found in somemarginal
zone lymphomas,25 and potential activating mutations or
mutations resulting in NOTCH2-reducted turnover have also
been detected in marginal zone lymphoma and in diffuse large
B-cell lymphomas (DLBCL).25,26 More recently, a fraction of
DLBCLs were shown to carry a truncated NOTCH2 mutation
that leads to partial deletion of the C-terminal PEST domain;
this deletion was shown to activate both NOTCH2 and NF-κB
signals and to promote the proliferation of B-cell lymphoma
cell lines.27 Characterization of tumor biopsies from Hodgkin
lymphoma patients revealed a strong expression of NOTCH in
Hodgkin–Reed–Stenberg tumor cells; activation of NOTCH
signaling in these cells promoted proliferation and provided
protection against apoptosis.28–30
Here, we found that activation of NOTCH2 signaling has an
important role in maintaining a homeostatic equilibrium
between B cells and the virus, being capable of keeping a
strictly latent EBV cycle. In particular, we demonstrate that
inhibition of NOTCH2 signaling by GSIs induces expression of
EBV lytic genes and triggers the induction of a complete lytic
cycle in both LCL and EBV-positive BL cells. As viral lytic
replication is associated with the death of infected cells, this
study suggests that, in addition to TERT, NOTCH2 may
constitute an important therapeutic target for EBV-driven
B-cell malignancies. It has recently been reported that
NOTCH2, activated via delta-like ligand 1, inhibits the EBV
lytic cycle in the EBV-infected B-cell non-Hodgkin’s lymphoma
line by upregulating the cellular transcription factor Zeb2,
which represses BZLF1 expression. Inhibition of NOTCH2
signaling led to disruption of EBV latency, with induction of
BZLF1 and the lytic cycle.56 Thus, our study provides
independent validation of the role of NOTCH2 in the balance
between latent and lytic status of EBV in infected B cells, albeit
by different mechanisms. The discovery of different mechan-
isms involved in the regulation of BZLF1 by NOTCH2 may
reflect the complex pathway that ensure EBV latency in
B cells.46
In this study, we also provide mechanistic insights demon-
strating that TERT can induce NOTCH2 expression at
transcriptional level. This is consistent with recent studies
indicating a telomere-independent role for TERT as a
transcriptional modulator of the Wnt/β-catenin and NF-κB
signaling pathways.35–37 In particular, we found that NF-κB,
but not the Wnt signaling, is involved in NOTCH2 promoter
induction by TERT. These results were observed with both an
NF-κB signaling inhibitor and a NOTCH2 luciferase promoter
reporter construct lacking two putative NF-κB binding motifs.
The involvement of the NF-κB pathway in NOTCH2 promoter
activation was also recently demonstrated by Wang et al.38
who reported that inflammatory cytokine-dependent induction
of NOTCH2 in nucleus pulposus cells requires direct inter-
action of the NF-κB/p65 protein with the NOTCH2 promoter.
Overall, the results of the present study provide new insights
into how cellular genes coordinately control EBV latency. In
particular, we demonstrate that TERT contributes to preserve
EBV latency through the NOTCH2 cellular pathway; as virus
latency is required for EBV-driven cell transformation, this
study suggests that NOTCH2 has a significant role in LCL
immortalization. Our finding that NOTCH2 inhibition triggers
the EBV lytic cycle and cell apoptosis is of particular
importance in the light of increasing interest in developing
strategies to reactivate EBV lytic gene expression in
latently infected tumor cells to treat overt EBV-associated
lymphomas.57–59 Several chemotherapeutic drugs are known
to trigger EBV replication, and the combination of antivirals
with lytic cycle inducers is emerging as a highly promising
strategy for the treatment of EBV-driven tumors.60,61 On these
grounds, our results also demonstrate that the antiviral drug
GCV can enhance the apoptotic effect induced by GSI
treatment in both LCL and EBV-positive BL. Our findings
therefore suggest that GSIs can be combined with other
drugs in therapeutic schedules aimed at inducing EBV lytic
reactivation against EBV-associated lymphomas. In this
respect, it will be of interest in future studies to assess whether
TERT inhibitors9 can synergize with GSIs.
Materials and Methods
Plasmids. Plasmids were provided as follows: a plasmid expressing luciferase
under the control of NOTCH2 promoter (pGL3N2PR-2327/99), a smaller NOTCH2
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reporter plasmid lacking two putative NF-κB binding motifs (pGL3N2PR-110)
and a plasmid expressing an S33Y-mutated β-catenin protein (pCGN-HA-S33Y-
βcatenin)33 obtained from Jonas Ungerback (Linkopings University, Linkoping,
Sweden); human TERT linked to EGFP in pEGFP (pEGFP–hTERT) and the control
empty vector pEGFP-C134 obtained from Chantal Autexier (Lady Davis Institute for
Medical Research, Jewish General Hospital, Montréal, Québec, Canada);
plasmids expressing the intracellular domain of NOTCH2 (pMigRI-ICN2 and
pMSCVpuro-ICN2) from Adolfo Ferrando (Columbia University, New York, NY,
USA); plasmid containing 800- bp fragment upstream of the TERT translational
start site, phTERTpromoterLuc62 from Riccardo Dalla Favera (Columbia
University).
Cell cultures. LCLs 4134, 4810, 4193, 4815 and 4141 were obtained by
infecting peripheral blood mononuclear cells from normal donors with EBV strain
B95.8. The establishment and characterization of these cell lines have been
previously described.3 We considered as ‘early LCLs’ cells within the first 30 culture
passages after EBV infection, and ‘late LCLs’ cell lines which underwent up to 90
culture passages after EBV infection.3 Cells (4134) expressing ectopic TERT (4134/
TERT+) and control cells (4134/BABE) were obtained by infecting parental
telomerase-negative cells with the pBABE retroviral vector, either containing or
lacking TERT cDNA, respectively.3 4134/MigRI-ICN2 and 4134/MSCVpuro-ICN2
cells were obtained by infecting 4134 cells with retroviral vectors expressing the
NOTCH2-ICD (pMigRI-ICN2 or pMSCVpuro-ICN2). Retroviral vectors were
generated by a transient three-plasmid vector packaging system, as previously
described.3 BL41 is an EBV-negative BL cell line, kindly provided by Martin Rowe
(Cancer Center, University of Birmingham, Birmingham, UK). BL41/B95.8 is the
counterpart cell line infected in vitro with EBV strain B95.8 and was kindly provided
by Martin Allday (Ludwig Institute for Cancer Research, London, UK). B95.8 cell line
is an EBV-positive marmoset lymphoblastoma cell line, which spontaneously has
around 5% of cells in the lytic cycle,63 was employed as positive control for lytic
protein expression. LCLs and BL41 cells were cultured in RPMI-1640 medium
(Euroclone, Milano, Italy), supplemented with 2% glutamine, 50 μg/ml gentamycin
(Sigma, St Louis, MO, USA) and 10% heat-inactivated fetal bovine serum (FBS;
Gibco, Milano, Italy; standard medium). BL41/B95.8 and B95.8 cells were cultured in
standard medium supplemented with 1 mM sodium pyruvate, 1% nonessential
amino acids (Sigma), and 50 mM β-mercaptoethanol. HCT116 and U2OS cells
were obtained from the American Type Culture Collection (Rockville, MD, USA) and
maintained in McCoy’s 5 A modified medium (Sigma) supplemented with 50 μg/ml
gentamycin (Sigma) and 10% heat-inactivated FBS (Gibco). All cell lines were
maintained in culture at 37 °C and 5% CO2.
To inhibit NOTCH signaling, cells in logarithmic growth were cultured in the
presence of compound E (CompE, EDM Millipore, Billerica, MA, USA) or
dibenzazepine (DBZ, EDM Millipore) at different doses with or without the pro-drug
ganciclovir (GCV; Sigma). Mock-treated cells were cultured in the presence of a
vehicle (DMSO) at a final concentration not exceeding 0.1%.
Reverse transcriptase PCR and real-time PCR. Total cellular RNA was
extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA). For reverse
transcriptase PCR (RT-PCR) and real-time PCR experiments, 1-μg RNA was retro-
transcribed into cDNA with the SuperScript III RNase reverse transcriptase assay
(Invitrogen) according to the manufacturer’s instructions. All TERT transcripts were
quantified by real-time PCR, as previously described.3 Real-time PCR reactions for
quantification of BATF and NOTCH2 transcripts were performed on a LightCycler
480 Real-Time PCR System (Roche, Basel, Switzerland). Each PCR was
conducted in 50 μl of mixture containing 25 μl Lightcycler 480 probe master
(Roche), 200 nM of fluorogenic probe, 900 nM of each primer and 10 μl of cDNA
samples. After 2 min at 50 °C to allow the uracil N-glycosylase to act, and after a
denaturation step of 10 min at 95 °C, 45 cycles were run, each for 15 s at 95 °C and
1 min at 60 °C. Samples were run in triplicate. Primers and probes for PCR analysis
were: BATF forward: 5′-GACAAGAGAGCCCAGAGGTG-3′; BATF reverse: 5′-GTAG
AGCCGCGTTCTGTTTC-3′; BATF probe: 5′-Cy5-TGGCAAACAGGACTCATCTG-
BBQ-3′; NOTCH2 forward: 5′-CAGCCTGTATGTGCCCTGTG-3′; NOTCH2 reverse:
5′-GTGCTCCCTTCAAAACCTGGA-3′; NOTCH2 probe: 5′-FAM-TCACCTTGTGT
CAATGGAGGC-BHQ-3′. Quantification of HES1 and JAG1 transcripts were carried
out by real-time PCR on an ABI PRISM 7900HT Sequence Detection System
(PE Biosystems, Foster City, CA, USA) by using Platinum SYBR Green qPCR
SuperMix-UDG (Invitrogen) and the following primers: HES1 forward: 5′-CAGC
GGGCGCAGATGAC-3′; HES1 reverse: 5′-CGTTCATGCACTCGCTGAAG-3′; JAG1
forward: 5′-TGAATGGGGGTCACTGTCAGA-3′; JAG1 reverse: 5′-CACCGTTCT
GGCAGGGATTAG-3′. Cycling conditions were 10 min at 95 °C, 60 cycles of 15 s at
95 °C and 1 min at 60 °C. For mRNA normalization, 10 μl of cDNA from each
sample were amplified for the hypoxanthine phosphoribosyltransferase 1 (HPRT1)
housekeeping gene, as described previously.64 TERT values were normalized for
104 copies of HPRT1. Relative quantification for NOTCH2, BATF, HES1 and JAG1
expression was carried out with the ΔΔCt method and HPRT1 as reference gene,
unless otherwise specified.
NOTCH2 transcripts were detected by the specific primer pair designed in the
ICD region: NOTCH2 forward: 5′-CTGGATGCAGGTGCAGATGCCAATGC-3′ and
NOTCH2 reverse; 5′-GCAGAAGTCAACACGGTGCCTGGAGG-3′.55 Viral BZLF1
and cellular housekeeping glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
gene transcripts were detected, as previously reported.65
All primer pairs of NOTCH2, BATF, HES1, JAG1, TERT, GAPDH and HPRT1
cellular genes were designed in different exons, separated by at least one intron to
avoid genomic DNA amplification during PCR reactions. Nevertheless, to account
for potential contamination by genomic DNA, control reactions without reverse
transcriptase (RT− ) were included in each plate. All RT− samples were negative,
as expected (not shown).
Telomerase activity assay. Telomerase activity was assessed with a PCR-
based telomeric repeats amplification protocol (TRAP) as previously reported.66,67
The TRAP assay was performed with 0.250 μg of total cell lysates.
Western blot. Western blot analyses were prepared as previously reported.68
The expression of viral EA-D and cellular NOTCH2-ICD, BATF, JAG1 and α-tubulin
were evaluated by monoclonal anti-EA-D (clone 6D1, Abcam, Cambridge, UK),
monoclonal anti-NOTCH2 (clone C651.6DbHN developed by Spyros Artavanis-
Tsakonas, obtained from the Developmental Studies Hybridoma Bank, developed
under the auspices of the NICHD and maintained by The University of Iowa,
Department of Biology, Iowa City, IA, USA), monoclonal anti-BATF (1G4; Novus
Biologicals, Cambridge, UK), polyclonal anti-JAG1 (H114; Santa Cruz Biotechnol-
ogy, Dallas, TX, USA) and clone B-512 (Sigma), respectively. Blots were incubated
with an appropriate peroxidase-conjugated secondary antibody (Sigma), and
stained with a chemiluminescence detection kit (SuperSignal West Pico
Chemiluminescent Substrate, Pierce, Rockford, IL, USA).
Immunohistochemistry. Cytospins were fixed in cold acetone (4 °C) for
10 min. Expression of gp350 protein was analyzed using the monoclonal antibody
clone 0221 (Abcam). After incubation for 1 h with the primary antibody,
immunostaining was performed with the avidin–biotin peroxidase complex (ABC
kit; Vector Laboratories, Burlingame, CA, USA), and 3–30 diaminobenzidine
chromogen as substrate (Dako, Glostrup, Denmark). The cells were lightly
counterstained with Mayer’s hematoxylin. The specificity of the staining procedure
was confirmed by replacing the primary antibody with PBS.
Luciferase reporter assay. HCT116 cells (4.5 × 105) were transiently
transfected with 1 μg of pGL3N2PR-2327/-99, serial dilution of pEGFP–hTERT, or
empty pEGFP-C1 and 0.5 μg cytomegalovirus β-galactosidase (pCMV-β-Gal). A set
of experiments were also conducted with a smaller NOTCH2 luciferase promoter
reporter construct (pGL3N2PR-110) instead of the longer pGL3N2PR-2327/-99. In
some experiments, cells were treated with the inhibitors XAV-939 (Selleck
Chemicals LLC, Houston, TX, USA) or N-AI (EDM Millipore) at the indicated
concentration 3 h before transfection. DMSO was employed as control. As positive
control, HCT116 were also co-transfected with pCGN-HA-S33Y-β-catenin a plasmid
known to activate the NOTCH2 promoter or with pcDNA3 as control plasmid.
Lipofectamine 2000 (Invitrogen) was used as a transfection reagent according to the
manufacturer’s instructions.
TERT-negative U2OS cells (3x105) were transiently transfected with 1.5 μg
phTERTpromoterLuc, 1 μg pMT2TMyc, or empty pMT2T, 1 μg pMigRI-ICN2 or
pMSCVpuro-ICN2, and 0.5 μg CMV- β-Gal by Lipofectamine 2000 (Invitrogen).
Luciferase and β-Gal activities were quantified with the Bright-Glo luciferase assay
and Beta-Glo system (Promega, Madison, WI, USA), respectively. Luciferase activity
was normalized to β-galactosidase activity and the data are presented as luciferase
activity compared with that of the control vector.
EBV genome quantification. EBV DNA from virus particles released in
culture supernatants were quantified by real-time PCR69 after ultracentrifugation
and DNase treatment, as previously reported.3
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Apoptosis analysis. Apoptosis was evaluated by staining cells with annexin V
and propidium iodide (PI, Roche), as previously detailed,68 and analyzed by flow
cytometry. At least 50 000 events were acquired, data were processed with
CellQuestPro software (BD Biosciences, Erembodegem, Belgium), and analyzed
with Kaluza Analyzing Software v1.2 (Beckman Coulter, Brea, CA, USA). Annexin
V-positive/PI-negative and annexin V-positive/PI-positive samples were classified as
early and late apoptotic cells, respectively, and both fractions were included in the
percentages of apoptotic cells.
Statistical analysis. For statistical comparisons, the Student’s t-test or the
Mann–Whitney U test were conducted with SPSS software version 21 (IBM,
Armonk, NY, USA). P-value o0.05 was considered to be statistically significant.
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